o-glcnac transferase

OSMI-1 is an O-GlcNAc transferase (OGT) inhibitor (IC50=2.7 μM) that is orally active and cell-permeable. OSMI-1 inhibits protein O-GlcNA acetylation without qualitatively altering cell-surface N- or O- linked glycans.

OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells) that can be used to study OGT inhibition in different human cell lines.

OGT inhibitor 4a is an O-linked n-acetylglucosaminyltransferase (OGT) inhibitor with anticancer activity for the study of autoimmune and neurological disorders.

OSMI-3 is a potent and cell-permeable inhibitor of O-GlcNAc transferase (OGT) for the study of cancer and cardiovascular disease.

OGT-IN-2 is a potent O-GlcNAc transferase (OGT) inhibitor. OGT-IN-2 inhibits sOGT and ncOGT with IC50 values of 30 μM and 53 μM, respectively[1]. OGT-IN-2 can be used for the research of articular diseases[1].

(Rac)-OSMI-1 is a racemate of OSMI-1. OSMI-1 is an inhibitor of O-GlcNAc transferase (OGT) (IC50: 2.7 μM). OSMI-1 inhibits protein O-linked N-acetylglucosaminoglycans (O-GlcNAcylation) in mammalian cell lines and does not qualitatively alter cell surface N- or O-linked glycans.

BZX2 is a novel inhibitor of O-GlcNAc transferase (OGT) activity.

BZX1 is an O-Iinked N-acetylglucosaminyltransferase inhibitor, which can be used to study abnormal cell differentiation and cartilage degeneration.